Every day, we strive to enhance our customers’ success through product innovation that continually drives down their cost per experiment. Our systems, including IFCs, instrumentation, and software, allow scientists to make incomparable leaps in productivity. Our product lines include:
The Company's patent portfolio consists of over 80 issued US patents and over 240 pending patents internationally, including those licensed from Caltech, Harvard, and University of Alabama.
1999 Founding of Fluidigm Corporation (originally Mycometrix) to commercialize IFC technology developed in the laboratory of biophysicist Stephen Quake, PhD.
2003 Launch of the TOPAZ® System for Protein Crystallization, including IFCs that assemble 768 crystallization conditions in parallel and instrumentation and software that automate the digital imaging and analysis of experiments.
2004 Development of IP around a new class of IFCs referred to as dynamic arrays and of prototypes yielding as many as 9,216 parallel data points.
2005 Opening of a 15,000 square-foot IFC fabrication facility in Singapore.
2006 Launch of the BioMark™ Real-Time PCR System, a multi-application hardware/software platform based on BioMark™ dynamic arrays. Introduction of BioMark™ digital arrays, heralded as a practical solution for ultra-sensitive detection by digital PCR.
2007 Launch of high-throughput genotyping on the BioMark system, a breakthrough for the study of genetic variation within large populations.
2008 Launch of the Fluidigm® EP1 System for genetic analysis.